Anzeige
Mehr »
Sonntag, 22.02.2026 - Börsentäglich über 12.000 News
NATO-Ostflanke LIVE: Lettland-Defence-Zertifikat! Diese Aktie öffnet die Tür zu bis zu 3 Mio. € Finanzierung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
127 Leser
Artikel bewerten:
(0)

Carrington Labs Shareholders Elect Directors, Approve Stock Option Plan at 2004 Annual Meeting

IRVING, Texas, May 21 /PRNewswire-FirstCall/ -- Shareholders at the 2004 annual meeting of Carrington Laboratories, Inc. elected former US Army Surgeon General Ronald R. Blanck, DO and former US Attorney General Edwin Meese III to the company's board of directors for terms ending in 2005.

Dr. Blanck and Mr. Meese were appointed to the board in June 2003, bringing the total number of board members to seven.

The shareholders re-elected R. Dale Bowerman and Thomas J. Marquez to terms expiring in 2007.

By unanimous vote, the shareholders approved proposals to amend the Employee Stock Purchase Plan and approve the 2004 Stock Option Plan.

Chairman of the board George DeMott said, "We are pleased and privileged to welcome Ron Blanck and Ed Meese as elected members of the board. They join an outstanding board that brings tremendous experience to bear on Carrington's exciting technologies and business opportunities."


Ronald R. Blanck, DO, 62, formerly Surgeon General of the US Army and commander of the US Army Medical Command, has been president of the University of North Texas Health Science Center at Fort Worth since August 2000 where he oversees a growing academic health center that includes the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, and School of Public Health. Dr. Blanck is a graduate of the Philadelphia College of Osteopathic Medicine and is board-certified in internal medicine. He began his military career in 1968 as a medical officer and battalion surgeon in Vietnam, and retired in 2000.

Edwin Meese III, 72, served as the 75th Attorney General of the United States from February 1985 to August 1988. From January 1981 to February 1985, he held the position of Counselor to the President. As Attorney General and as Counselor, Mr. Meese was a member of President Reagan's cabinet and the National Security Council. He currently holds the Ronald Reagan Chair in Public Policy at The Heritage Foundation, a Washington-based public policy research and education institution where he also serves as chairman of the Center for Legal and Judicial Studies. Before joining Governor Reagan's staff in 1967, Mr. Meese was a business executive in the aerospace and transportation industries, serving as vice president for administration of Rohr Industries, Inc. in Chula Vista, California. He left Rohr to return to the practice of law. Mr. Meese is a graduate of Yale University and holds a law degree from the University of California at Berkeley. He is a retired colonel in the United States Army Reserve. He is active in numerous civic and educational organizations and is the chairman of the governing board of George Mason University in Northern Virginia.

Thomas J. Marquez, 65, a former officer and director of Electronic Data Systems, Inc. (EDS), has been a director of the company since August 1987. From August 1987 until May 1990, he was chairman of the board and chief executive officer of Carrington. Since his resignation as an officer of Electronic Data Systems, he has been engaged primarily in personal investment activities and a number of public service projects. Mr. Marquez is a director of Aquinas Funds, Inc.

Selvi Vescovi, 73, former head of international operations at The Upjohn Company, has been a director of Carrington since May 1989. He was chairman of the board from May 1990 to April 1995 and interim president and chief executive officer from March 1995 to April 1995. He retired from Upjohn in 1988 from his positions as corporate vice president and president and general manager of Upjohn International, Inc. Mr. Vescovi served as adjunct professor, International Management, at Western Michigan University from 1988 to 1993 and as a member of the Advisory Board of the College of Business Administration of the University of South Carolina from 1988 to 1994.

The 2004 Annual Meeting included presentations by CEO and president Carlton E. Turner, PhD, DSc, and Kenneth Yates, DVM, president of Carrington's wholly owned subsidiary, DelSite Biotechnologies, Inc, a developer of novel drug delivery technologies.

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products under the AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The Company's DelSite Biotechnologies subsidiary is developing its propriety GelSite(TM) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com/.

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed May 13, 2004.

Carrington, Manapol, AloeCeuticals, Hydrapol, GelSite, GelVac and Acemannan Hydrogel are trademarks, registered trademarks or service marks of Carrington Laboratories, Inc., in the United States and other countries. All other trademarks or service marks contained herein are the properties of their respective owners.

Carrington Laboratories, Inc.
© 2004 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.